California State Teachers Retirement System reduced its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 5.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,529,166 shares of the medical equipment provider’s stock after selling 154,173 shares during the quarter. California State Teachers Retirement System owned about 0.18% of Boston Scientific Corporation worth $70,108,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Acrospire Investment Management LLC increased its stake in Boston Scientific Corporation by 157.3% during the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock worth $141,000 after acquiring an additional 3,100 shares during the last quarter. Guardian Life Insurance Co. of America increased its stake in Boston Scientific Corporation by 0.9% during the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock worth $131,000 after acquiring an additional 49 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in Boston Scientific Corporation by 14.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock worth $160,000 after acquiring an additional 720 shares during the last quarter. San Francisco Sentry Investment Group CA bought a new stake in Boston Scientific Corporation during the second quarter worth approximately $191,000. Finally, Peddock Capital Advisors LLC bought a new stake in Boston Scientific Corporation during the second quarter worth approximately $201,000. 90.44% of the stock is currently owned by institutional investors.
In other Boston Scientific Corporation news, SVP John Bradley Sorenson sold 2,100 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $27.15, for a total value of $57,015.00. Following the completion of the transaction, the senior vice president now owns 18,880 shares of the company’s stock, valued at approximately $512,592. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Timothy A. Pratt sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $26.67, for a total transaction of $266,700.00. Following the completion of the transaction, the executive vice president now directly owns 195,846 shares of the company’s stock, valued at approximately $5,223,212.82. The disclosure for this sale can be found here. Insiders sold a total of 531,297 shares of company stock valued at $15,144,095 in the last three months. 0.74% of the stock is currently owned by corporate insiders.
Shares of Boston Scientific Corporation (NYSE:BSX) traded up 0.31% during mid-day trading on Tuesday, hitting $29.42. The company had a trading volume of 1,105,806 shares. Boston Scientific Corporation has a 52-week low of $19.67 and a 52-week high of $29.54. The firm has a 50-day moving average price of $28.37 and a 200 day moving average price of $27.07. The firm has a market capitalization of $40.37 billion, a price-to-earnings ratio of 52.63 and a beta of 1.09.
Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter last year, the company posted $0.27 EPS. The firm’s revenue was up 6.2% compared to the same quarter last year. Analysts expect that Boston Scientific Corporation will post $1.26 earnings per share for the current year.
Boston Scientific Corporation Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).
What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.